SCHEMBL13050810

SCHEMBL13050810

CN1CCCC2(CCN(C(C)(C)C)C2)C1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP2 O75604 4/20 0.44
CYP1A2 P05177 2/20 0.39
CYP3A4 P08684 9/20 0.38
TSHR P16473 6/20 0.38
CYP2D6 P10635 4/20 0.38
CYP2C9 P11712 2/20 0.38
HSD17B10 Q99714 2/20 0.38
CYP2C19 P33261 3/20 0.38
ALDH1A1 P00352 1/20 0.35
HIF1A Q16665 1/20 0.35
GRIN2D O15399 1/20 0.31
GRIN3B O60391 1/20 0.31
CHRM2 P08172 1/20 0.31
CHRM1 P11229 1/20 0.31
OPRM1 P35372 1/20 0.31
GRIN1 Q05586 1/20 0.31
KCNH2 Q12809 1/20 0.31
GRIN2A Q12879 1/20 0.31
GRIN2B Q13224 1/20 0.31
GRIN2C Q14957 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17886517 0.94 USP2 (0.41) USP2CYP1A2CYP3A4TSHRCYP2D6
SCHEMBL15112835 0.92 CYP3A4 (0.41) USP2CYP1A2CYP3A4TSHRCYP2D6
SCHEMBL24363770 0.90 USP2 (0.49) USP2CYP1A2CYP3A4TSHRCYP2D6
SCHEMBL13697423 0.90 CYP3A4 (0.34) USP2CYP1A2CYP3A4TSHRCYP2D6
SCHEMBL19104238 0.88 USP2 (0.42) USP2CYP1A2CYP3A4TSHRCYP2D6
SCHEMBL16624956 0.88 GRIN2D (0.34) USP2GRIN2DGRIN3BCHRM2CHRM1
SCHEMBL25738932 0.84 USP2 (0.35) USP2CYP1A2CYP3A4TSHRCYP2D6
SCHEMBL17281976 0.84 GRIN2D (0.34) USP2GRIN2DGRIN3BCHRM2CHRM1
SCHEMBL16117658 0.83 GRIN2D (0.39) GRIN2DGRIN3BCHRM2CHRM1OPRM1
SCHEMBL24363769 0.82 USP2 (0.38) USP2CYP1A2CYP3A4TSHRCYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240066029-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2024-02-29 US disclosed
US-10555944-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors ELI LILLY AND COMPANY (US) 2020-02-11 US disclosed
US-20180133200-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2018-05-17 US disclosed
US-20180133213-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2018-05-17 US disclosed
US-20180134702-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2018-05-17 US disclosed
US-9527876-B2 Prodrugs of bicyclic substituted pyrimidine type PDE-5 inhibitors Xuanzhu Pharma Co., Ltd. (CN) 2016-12-27 US disclosed
US-9359371-B2 Bicyclic substituted pyrimidine compounds Xuanzhu Pharma Co., Ltd. (CN) 2016-06-07 US disclosed
US-20160046654-A1 Prodrugs Of Bicyclic Substituted Pyrimidine Type PDE-5 Inhibitors Xuanzhu Biopharmaceutical Co., Ltd. (CN) 2016-02-18 US disclosed
US-20150232474-A1 Bicyclic Substituted Pyrimidine Compounds Xuanzhu Biopharmaceutical Co., Ltd. (CN) 2015-08-20 US disclosed
US-8980904-B2 Heterocyclic substituted pyrimidine compound Xuanzhu Pharma Co., Ltd. (CN) 2015-03-17 US disclosed
US-20140288063-A1 Heterocyclic Substituted Pyrimidine Compound Xuanzhu Pharma Co., Ltd. (CN) 2014-09-25 US disclosed
US-8399465-B2 Compounds with two fused bicyclic heteroaryl moieties as modulators of leukotriene A4 hydrolase JANSSEN PHARMACEUTICA NV (BE) 2013-03-19 US disclosed
US-20100292208-A1 COMPOUNDS WITH TWO FUSED BICYCLIC HETEROARYL MOIETIES AS MODULATORS OF LEUKOTRIENE A4 HYDROLASE JANSSEN PHARMACEUTICA NV (BE) 2010-11-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180134702-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, ROR1, BRAF USP2 3575/4885CYP1A2 3812/4885CYP3A4 3158/4885
US-20100292208-A1 COMPOUNDS WITH TWO FUSED BICYCLIC HETEROARYL MOIETIES AS MODULATORS OF LEUKOTRIENE A4 HYDROLASE LTA4H, LTC4S, LTB4R USP2 2233/4885CYP1A2 680/4885CYP3A4 140/4885
US-10555944-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors RET, ROR1, BRAF USP2 3575/4885CYP1A2 3812/4885CYP3A4 3158/4885
US-20150232474-A1 Bicyclic Substituted Pyrimidine Compounds DPYD, UMPS, TYMP USP2 4361/4885CYP1A2 516/4885CYP3A4 341/4885
US-20140288063-A1 Heterocyclic Substituted Pyrimidine Compound PDE3B, PDE5A, PDE3A USP2 4154/4885CYP1A2 1019/4885CYP3A4 1076/4885
US-20180133200-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, ROR1, BRAF USP2 3575/4885CYP1A2 3812/4885CYP3A4 3158/4885
US-20180133213-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, ROR1, BRAF USP2 3575/4885CYP1A2 3812/4885CYP3A4 3158/4885
US-20160046654-A1 Prodrugs Of Bicyclic Substituted Pyrimidine Type PDE-5 Inhibitors PDE5A, PDE3A, PDE7A USP2 2245/4885CYP1A2 265/4885CYP3A4 232/4885
US-20240066029-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, ROR1, BRAF USP2 3575/4885CYP1A2 3812/4885CYP3A4 3158/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.